医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Anji Pharma Adds Clinical Sites to Accelerate Clinical Development of Pradigastat for the Treatment of Functional Constipation

2021年04月15日 PM10:00
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass. & SHANGHAI

Anji Pharma has initiated dosing in the U.S. and China as part of a Phase 2 program for pradigastat (ANJ908) in functional constipation. Pradigastat, a first-in-class inhibitor of diacylglycerol acyl transferase 1 (DGAT1), has a robust safety and pharmacodynamic profile that has been rigorously established across multiple clinical studies.

Chronic constipation affects nearly one in seven Americans, with nearly two million patients seeking pharmacotherapy options worldwide. In addition to functional constipation, related conditions where pradigastat may have clinical benefit include irritable bowel syndrome-associated and opioid-induced constipation.

“Despite the prevalence of chronic constipation, current treatment options are desperately lacking, with low response rates typical for all approved medications,” said Dan Meyers, M.D., Chief Medical Officer of Anji. “Based on our analysis of existing clinical data, we anticipate pradigastat will offer patients and physicians a significantly higher response rate, and we look forward to sharing the data as it becomes available.”

To accelerate bringing medicines to patients across the globe, Anji has synchronized development in North America and Asia to allow new drug application (NDA) filings in near-simultaneous fashion across major markets. Anji’s Phase 2 study with pradigastat will enroll approximately 180 patients at clinical sites in U.S. and China. Patients will receive pradigastat tablets (20 or 40 mg) or placebo once daily for four weeks and evaluated for improvements in constipation measures (ClinicalTrials.gov Identifier NCT04620161).

Anji holds pradigastat development and commercial rights for constipation-related disorders in all global markets, including U.S., Europe, and Asia.

About Anji Pharma

Anji Pharma is a clinical-stage company dedicated to bringing life-changing therapies to patients as efficiently as possible. Taking inspiration from its namesake bridge in Hebei Province, Anji strives to “Aid Those in Need,” while building connectivity across patient-centric ecosystems. In addition to pradigastat, Anji is developing delayed-release metformin (ANJ900) for effective glucose management in patients with type 2 diabetes and advanced chronic kidney disease. Global pivotal trials for ANJ900 are expected to initiate by mid-2021. For more info, visit www.anjipharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005033/en/

CONTACT

Corporate Contact: Michael Serrano-Wu, Ph.D., Anji Pharma, info@anjipharma.com

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8092

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates
  • Exome-Backed Broncus Holding Corporation Launches Hong Kong Public Offering
  • Saladax Biomedical宣布Salvatore J. Salamone博士荣获著名的C.E. Pippenger博士奖
  • IHMA在上海建立微生物学参考实验室,进一步支持全球抗感染产品的发现和开发
  • Rhizen Pharmaceuticals AG宣布,RP7214治疗新冠肺炎患者2期研究进行首例患者给药